26th Pharmacovigilance Conference 2021

26th Pharmacovigilance Conference 2021 is organized by Virtue Insight and will be held on Nov 11, 2021.

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

Who Should Attend and Who You’ll Meet:
CIOs, CEOs, CDOs, Vice Presidents, Presidents, Heads, Directors and Team Leaders from the following areas:
• Pharmacovigilance Strategy
• Drug Safety/Risk Management
• Information and Clinical Data Management
• Clinical Research
• Research & Development
• Product Safety/Assurance Assessment
• Patient Safety & Outcomes Research & Data Analysis
• Epidemiology project management
• Regulatory Affairs and Compliance
• Sales & Marketing
• Biotech manufacturers

From the following:
• Pharmaceutical organizations
• Generic pharmaceutical companies
• Contract research organizations
• Patient recruitment companies
• Government- Department of health
• Non-profit organizations/ Association
• Consultants

Conference Introduction: 
Virtue insight’s 26th Pharmacovigilance Conference is more than a traditional conference. It is a unique opportunity to learn about the latest trends, to engage with renowned experts, and to personally develop as a healthcare professional. Take this opportunity to learn from regulators and leading experts and discover what the challenges and opportunities will be in the field of Pharmacovigilance in 2021. Do not miss out on these exciting discussions. Join us virtually to discover and learn from the experts who will be joining us on 11th November 2021.

According to recent report, the worldwide market for PV outsourcing was worth more than $3.8 billion in 2019, and will expand at a compound annual growth rate of around 15.8% to reach $10.6 billion in 2026. One factor in this dynamic growth is sharp year-to-year increases in PV reporting to regulatory authorities. The global pharmacovigilance market size is expected to reach USD 14.95 billion by 2028. It is expected to expand at a CAGR of 11.5% from 2021 to 2028.

The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services. ADRs are responsible for almost 1,300,000 emergency department visits annually. Estimated the cost of ADR related hospitalizations in 2011 to be US $38.9 billion dollars.

Why Should You Attend?
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Key Themes Discussed:
• Signal detection and medical devices in PV
• How to improvise where medical devices help to improve the quality of patient care?
• Better standardization and review of REMS
• Challenges and impact of new technology in PV
• How to do better quality management system?
• What are the recent changes in Pharmacovigilance Guidelines?
• Recent improvements in COVID-19 Vaccine Research in PV – What to learn from it for future?
• Patient centric in Pharmacovigilance – Placing patients first
• Challenges in monitoring the patient in PV and Clinical trials
• Usage of electronic health records (EHR)
• Patient safety monitoring in social media: What are the troubles?
• Current Risk Management planning strategies in PV
• Current trends in PV Audits and Inspections
• Machine learning for detection of signals? How ML improve the PV than before?
• Real World Evidence in PV
• Impact of AI in Pharmacovigilance and how data analytics are increase the speed of PV?
• Automation leads the way of Future PV
• Risk and awareness of Robotics in PV
• New regulatory guidelines
• Be part of a major networking opportunity

Key Speakers:
• K BANGARURAJAN, Adviser, CDSCO (New Delhi)
• KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen (USA)
• SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda (Belgium)
• KLAUDIJA MARIJANOVIC BARAC, Sr Director, Global Patient Safety & PhV, Teva(UK)
• ROHAN MANE, Director, Risk Management Product Lead, Pfizer (UK)
• TEA BABIC, Director, PV Audits and Inspections, Teva Pharmaceuticals (UK)
• MAHESH MURTHY, Sr. Director of Operations - Medical Device, Biocon
• SUBHASH C MANDAL, Vice President and Chairman, Regulatory Affairs Division, Indian Pharmaceutical Association
• ANIL KUKREJA, Vice President - Medical Affairs and Regulatory, AstraZeneca
• NISHITH TYAGI, Director (Data Science and AI Solutions), Novartis
• PRAVEEN RAJ, Senior Director Medical Affairs, Biocon
• RAJEEV SHRIVASTAVA, Associate Director -Regulatory Affairs and Pharmacovigilance, Eli Lilly
• VAIBHAV CHOUDHARY, Associate Director Global Medical, Clinical & Regulatory Affairs, Fresenius Kabi
• KAVITA LAMROR, Director, Real World Investigator, Sanofi
• KARTHIKEYAN KUMARAN, Associate Director of Information Technology, AstraZeneca
• MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates
• DNYANESHWAR SANAP, EU/UK QPPV, Head Regional Pharmacovigilance, Glenmark (Germany)
• AVINASH R. KAKADE, SGM, Global Head –Pharmacovigilance, Lupin
• VEENA RAJAN, Head Mature Products PV, Global Patient Safety, AstraZeneca
• JAIDEEP GOGTAY, Chief Medical Officer, Cipla
• GEETA SHANBHAG, Sr. General Manager –Pharmacovigilance & Medico-regulatory Affairs, Ipca Laboratories
• JYOTSNA PATWARDHAN, Cluster Head, PV Country Quality, Novartis
• JAMAL ANWAR, Country Head Pharmacovigilance, Merck Sharp and Dhome
• INDU NAMBIAR, Head Pharmacovigilance, Boehringer Ingelheim
• VALLABH DESHPANDE, Head of Global PV Operations, Glenmark
• VISHWAS SOVANI, Founder Director, Pharamwisdom
• RAJENDRA KUMAR KASI, Head - Global Pharmacovigilance, Zydus Cadila Healthcare
• ROSHAN PAWAR, Associate General Manager, Alkem Laboratories
• RAGHDA MOHAMED, PV Cluster Lead Middle East & Turkey, Takeda (UAE)
• VARSHA NARAYANAN, Founder-Director, Dr Varsha’s Health Solutions
• SAKSHI SHRIVASTAVA DESAI, Global Medical- PV Compliance Strategy and Analytics, Johnson & Johnson
• GAYATHRI DEVI RAVICHANDRAN, Associate Manager - Regional Safety Operations, Merck
• KAVYA KADAM, Consultant, Global Clinical Trials

Plus more joining soon